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Genomic sequencing in acutely ill infants: what will it take to 
demonstrate clinical value?
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Proponents of rapid genomic sequencing in infants in neonatal or pediatric intensive care 
units (NICU/PICUs), which includes both rapid genome sequencing (rGS) and rapid exome 
sequencing (rES), argue that it can deliver timely diagnostic results and enable life-changing 
clinical interventions. Moreover, it has been suggested that this application could serve as a 
“breakthrough” to the widespread clinical use of next generation sequencing (NGS) tests.1 
On the other hand, payers might resist agreeing to pay for NGS in acutely ill infants for fear 
of establishing a precedent for reimbursement for NGS in much larger patient populations.
In this issue, a group of international experts has prepared a white paper that acknowledges 
the “great promise” of genome-wide sequencing (GWS) for acutely ill infants but 
emphasizes gaps in evidence.2 Friedman and colleagues lay out principles for establishing 
the clinical value of such testing. We agree that it is essential that a robust evidentiary base 
of benefits be developed to allow health-care providers and payers to make informed 
decisions on the implementation of NGS technologies in that patient population.
Friedman and colleagues propose that the first step in demonstrating clinical value of NGS 
in acutely ill children is the demonstration of analytic validity. Analytic validity is an 
important laboratory metric, and it is a crucial requirement for population screening to 
minimize false-positive and false-negative results. However, for ill patients, the important 
criteria are whether testing identifies pathogenic variants that explain disease phenotypes 
and whether timely return of results affects patient management and outcomes. Given the 
complexity of assessing analytic validity for thousands of gene variants, we suggest that the 
key to broad clinical implementation of NGS in this patient population is demonstrated 
evidence of clinical utility.
Friedman et al. suggest that mortality is the most compelling summary measure of the value 
of NGS compared with standard of care in this population, but we are skeptical for two 
reasons. First, as the authors cogently explain, diagnosis of an untreatable condition based 
on NGS results may lead to cessation of painful and ultimately futile procedures.2 For those 
infants, early genomic diagnoses may lead to earlier death while simultaneously reducing 
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suffering for the child and psychosocial harm to the parents through earlier transition to 
palliative care. Infants who have treatable conditions can benefit from initiation of 
appropriate treatment in terms of quality of life, but the extent to which treatment affects 
survival is not necessarily known. We propose reductions in total number of hospital days as 
a summary measure of nonfatal outcomes associated with timely genomic diagnoses in 
acutely ill infants.
Friedman and colleagues conclude, “Comparing diagnostic GWS to the current standard of 
care per case of serious genetic disease diagnosed can provide a practical means of assessing 
clinical value” and propose, “for a comparative study to provide the robust evidence that is 
needed, both costs and benefits will have to be collected in a rigorous prospective manner, 
and the results will need to be analyzed comprehensively.”2 We concur. Indeed, several 
cohort studies and randomized trials have either been published or are underway that are 
tracking health outcomes and costs associated with genomic diagnoses in acutely ill 
children. In particular, evidence shows that short-term cost savings from a shortening of the 
diagnostic process and from reduced inpatient costs for those infants who experience 
substantial health improvements can more than pay for the cost of sequencing and clinical 
interpretation. We need to draw lessons from that emerging body of clinical research and 
discuss how such analyses can be replicated and extended to address long-term costs and 
health outcomes from both the health-care and societal perspectives. We propose that to 
address the societal implications of this technology, researchers assess spillover costs and 
benefits to patients and families.3 In addition, families may value a genetic diagnosis for a 
sick child even if the diagnosis is not of immediate clinical benefit. The “personal utility” of 
genomic diagnoses can reflect prognostic value, the hope of a cure in the future, and 
increased knowledge of genetic risk for other family members, among other 
considerations4,5
Stark and colleagues recently demonstrated improved care and net cost savings from 
singleton rES of critically ill infants and children cared for at the Royal Children’s Hospital 
and Monash Children’s Hospital in Melbourne, Australia.6 In this study 40 critically ill 
children aged 3 days to 4 years were enrolled with parental consent for rES based on clinical 
consensus of a possible genetic etiology. A genomic diagnosis was found at a median of 16 
days for 52.5% of the 40 infants. A change in management occurred in 14 (35%) of the 
patients sequenced, including 2 children who were redirected to palliative care. In 2 
children, rES resulted in much more rapid diagnosis than was achieved through standard 
testing. Total cost of sequencing the cohort was AU$158,360, and the total cost of all 
examinations was AU$281,143. Estimated potential avoided cost of acute care based on 
reduced length of stay for 2 children who achieved earlier diagnosis with rES was AU
$543,178. One child with a riboflavin transporter defect was estimated to have had 115 
PICU days with mechanical ventilation avoided with rES. Relative to the estimated costs 
associated with traditional diagnostic testing, net health-care savings were estimated at AU
$262,035.
Similarly, a study at the Rady Children’s Institute of Genomic Medicine in San Diego, 
California retrospectively assessed 42 critically ill children less than 1 year old who received 
rGS.7 Of 42 patients sequenced, 18 received a diagnosis, of which 13 received significant 
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changes in management as a result. In 7 (17%) very ill infants, rGS was performed with 
interpretation in 2 days; the remaining 35 (83%) families received rGS with interpretation in 
5 days. Total cost for sequencing the 42 infants and, in 39 cases other family members, was 
$674,645. The relatively high cost compared with the Melbourne study reflected the 
increased speed to interpretation, the use of rGS rather than rES, and the frequent 
performance of trios (child and two parents). If singleton (proband-only) sequencing had 
been conducted, the cost would have been about one-half as much. Cost savings were 
assessed in six patients for whom physicians agreed that medical changes were attributable 
to the rapid genomic diagnosis. The estimated total avoidable cost was $803,199, with an 
aggregate reduction of 124 hospital days. A conservative estimate of net cost savings after 
subtracting the cost of rGS was $128,554. That included savings of $327,506 for a patient 
with Coffin-Siris syndrome associated with a ARID1B variant who was moved to comfort 
care when the diagnosis was made, thereby avoiding a planned 6-week stay in the NICU for 
antibiotic treatment.7 If the diagnosis and transition to palliative care had occurred 
substantially sooner, short-term cost savings could have been as much as an additional $1.2 
million.8 A child with Ohtara syndrome associated with a KCNQ2 variant (https://
www.radyfoundation.org/about-us/patient-stories/sebastiana) was diagnosed in 4 days, 
compared with 42 days for a child previously diagnosed using genome sequencing, avoiding 
38 hospital days and $181,141 in additional cost.7
A randomized trial of rGS would provide more definitive evidence of benefit, but it may not 
be feasible to enroll sufficient numbers of evidence for a trial to be adequately powered to 
test the hypothesis of clinical benefit. A trial in a NICU population is being conducted at 
Boston Children’s Hospital as part of the BabySeq project under the Newborn Sequencing 
In Genomic medicine and public HealTh (NSIGHT) consortium funded by the National 
Human Genome Research Institute;9 no results have been released (http://
www.genomes2people.org/babyseqproject/). The window to conduct trials in a NICU 
population may be closing as observational evidence of diagnostic benefit accumulates. A 
small trial of rGS in acutely ill infants intended to assess the impact on age at diagnosis was 
stopped early because of a high crossover rate in the control arm, the majority of whom 
received genomic sequencing, resulting from a loss of equipoise.10 Even though rGS is not 
yet standard of care, it may become increasingly difficult to enroll families in a trial in which 
some acutely ill infants are sequenced while others with similar symptoms are denied the 
same opportunity.
Real-world (observational) data is therefore likely to remain the primary source of 
information on the benefits of NGS in acutely ill infants. While both the Melbourne and San 
Diego studies showed net reductions in the short-term cost of acute hospital care, a complete 
analysis of economic benefits associated with a timely genomic diagnosis would require 
estimates of long-term health outcomes and health-care costs. Further, spillover effects on 
parental psychological stress and the burden of informal care and lost work time are 
important for economic analyses from the societal perspective.3 The cost of supportive care 
for a child with a permanent neurological condition can comprise a large fraction of total 
economic cost. Initiatives to develop and link real-world data on cohorts of infants who 
undergo rapid NGS in NICU/PICU settings in multiple centers and their families’ 
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experiences could generate the kinds of data needed for complete assessments of health and 
economic outcomes. Similar initiatives have been proposed in cancer genetics.11
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